Shilpa Medicare Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing authorization.".
Shilpa Medicare Limited Press Release Sep 11 2026
Earlier from Shilpa Medicare
- Shilpa Medicare Limited Press Release Jun 30 2026
- Shilpa Medicare Limited Press Release Jun 24 2026
- Press Release Jun 03 2026
- SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America